603963.SS
Dali Pharmaceuticalco.,Ltd [603963.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
603963.SS Stock Summary
In the News
603963.SS Financial details
Company Rating
-
Market Cap
2.02B
Income
-21.61M
Revenue
105.16M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
289
Optionable
No
Shortable
Yes
Earnings
22 Apr 2021
P/E
-116.86
Forward P/E
-
PEG
24.24
P/S
23.94
P/B
6.55
P/C
-
P/FCF
-79.41
Quick Ratio
3.64
Current Ratio
4.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
-57.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-19.9%
Revenue Q/Q
-39.59%
EPS Q/Q
-44%
-
-
-
-
SMA20
-26.71%
SMA50
-63.69%
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-5%
ROE
-5%
ROC
-0.05%
Gross Margin
40%
Oper. Margin
-19%
Profit Margin
-21%
Payout
-9%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.24-15.97
52W High
-92.13%
52W Low
-76.4%
RSI
14.17
Rel Volume
-
Avg Volume
12.29M
Volume
Perf Week
0%
Perf Month
-40.4%
Perf Quarter
-
Perf Half Y
-62.3%
-
-
-
-
Beta
0.245
-
-
Volatility
0%, 0.27%
Prev Close
0%
Price
1.18
Change
0%
Company Profile
- Volume Average 12.29M
- Market Capitalization 2.02B
- Employee 289
- CEO Mr. Jun Xiang Yang
- Headquarters Dali,CN
- IPO Date 2017-09-22
-
Website
https://www.daliyaoye.cn 
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.
